Teva's Olanzapine LAI Shows Positive Phase 3 Results for Schizophrenia
β’ Teva presented Phase 3 SOLARIS trial data showing Olanzapine LAI significantly improved social functioning and quality of life in schizophrenia patients.
β’ The study reported no cases of Post-Injection Delirium/Sedation Syndrome (PDSS) with Medincell's subcutaneous delivery technology.
β’ Real-world data on UZEDY demonstrated high adherence rates among schizophrenia patients with social vulnerabilities.
β’ UZEDY's usage data highlights the need for innovative treatments to address the challenges faced by individuals with schizophrenia.
Teva's TEV-749 Shows Promise in Schizophrenia Treatment with No PDSS Incidence
β’ Teva's TEV-749, a once-monthly subcutaneous olanzapine injection, significantly improved schizophrenia symptoms in a Phase 3 trial, meeting its primary endpoint.
β’ The SOLARIS trial demonstrated statistically significant improvements in PANSS, CGI-S, and PSP scores compared to placebo at week 8 across three dosing groups.
β’ Notably, no cases of post-injection delirium/sedation syndrome (PDSS) were observed, a significant advantage over existing long-acting olanzapine treatments.
β’ The safety profile of TEV-749 was consistent with oral olanzapine, with long-term safety data expected in the first half of 2025.
Β© Copyright 2025. All Rights Reserved by MedPath